• Maurizio Tonato, Rebecca A Clark-Snow, David Osoba, Albano Del Favero, Enzo Ballatori, and Sussanne Borjeson.
• Division of Medical Oncology, Policlinico Hospital, Via Brunamonti 51, 06122 Perugia, Italy. mtonato@unipg.it
• Support Care Cancer. 2005 Feb 1; 13 (2): 109-11.

AbstractFor patients treated with low or minimally emetogenic chemotherapy there is little evidence from clinical trials supporting the choice of a given antiemetic therapy or of any treatment at all. The panel recognized the necessity of considering the introduction into clinical practice of new agents in these categories, particularly oral cytotoxic agents and targeted biological agents and also the possibility of over-treatment with antiemetics. There was consensus among panel members regarding the recommended treatment for patients receiving chemotherapy agents with low and minimal emetic risk. Patients without a history of nausea and vomiting for whom minimally emetic risk chemotherapy is prescribed should not routinely receive antiemetic prophylaxis. A single agent such as a low-dose corticosteroid is suggested for patients receiving agents of low emetic risk. If nausea and vomiting occurs during subsequent cycles of chemotherapy, prophylaxis with a single agent such as a substituted benzamide, a corticosteroid, or a phenothiazine should be administered. Only patients with persistent nausea and vomiting despite treatment with these recommended agents should receive a 5-HT3 receptor antagonist in the following cycles.

12 keywords...

hide…